<DOC>
	<DOCNO>NCT03021642</DOCNO>
	<brief_summary>This Phase I , open label , randomize , crossover trial investigate relative bioavailability tepotinib healthy volunteer . Twenty-four volunteer randomize one two treatment sequence : Sequence A : test , reference , Sequence B : reference , test . The reference treatment refers current Phase II film-coated tablet ( 5 * 100 milligram ( mg ) tepotinib film-coated tablet ) test treatment new Phase III film-coated tablet ( 1 * 500 mg film-coated tepotinib tablet ) .</brief_summary>
	<brief_title>Relative Bioavailability Two Tepotinib Film-Coated Tablet Formulations Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Healthy male nonfertile , healthy female volunteer , 18 60 year age ( inclusive ) time informed consent . Written informed consent give trial related activity perform . Body weight great 50 kg body mass index ( BMI ) 18 kilogram per meter square ( kg/m^2 ) 30 kg/m^2 ( BMI = weight [ kg ] /height [ m^2 ] ) screening . Has vital sign follow normal range : Oral body temperature : 35.5 37.5 degree celsius ( °C ) Blood pressure ( BP ) pulse rate least 5 minute rest , measure supine position : Systolic blood pressure : 90 150 millimeter mercury ( mm Hg ) ; Diastolic blood pressure : 40 90 mm Hg Pulse rate : 35 110 beat per minute ( bpm ) Nonsmoker ( = 0 cigarette , pipe , cigar , ecigarettes , others ) least 6 month prior screen Women must postmenopausal least 2 year , confirm luteinizing hormone ( LH ) folliclestimulating hormone ( FSH ) assessment perform screening , surgically sterile ( , hysterectomy , oophorectomy ) . Pregnancy assessment also perform female volunteer screen admission . Males must agree use female partner use highly effective medically acceptable method contraception period participation trial least 3 month last treatment administration . Men must refrain donate sperm 3 month last treatment administration . Ability understand full nature purpose trial , include possible risk adverse effect ; ability cooperate Investigator comply requirement entire trial , include dietary restriction . Any condition , include finding medical history , physical examination pretrial assessment opinion Investigator , constitute risk contraindication participation volunteer trial could interfere trial objective , conduct evaluation . Any clinically relevant abnormality result screen safety laboratory parameter . Specifically Alanine transaminase ( ALT ) , aspartate aminotransferase ( AST ) , total bilirubin , Alkaline phosphatase ( ALP ) , amylase , lipase must exceed upper limit normal range . Any clinically relevant abnormality 12lead electrocardiogram recording . Positive result virology test hepatitis B surface antigen ( HBsAg ) , hepatitis C virus antibody ( antiHCV ) , human immunodeficiency virus antibody ( antiHIV 1 2 ) screening . History clinically relevant renal , cardiovascular , pulmonary disease , endocrinology disorder . History clinically relevant gastrointestinal disease , particular pancreatic disease , cholecystitis , liver disease hepatic dysfunction . History psychiatric neurological disorder ( depression , epilepsy etc. ) . Known hypersensitivity tepotinib excipients . Presence history serious allergy ( require hospitalization prolong systemic treatment ) . Presence drug alcohol abuse , confirm positive test result drug abuse alcohol history drug alcohol abuse past 3 year . Volunteers consume 14 ( female volunteer ) 21 ( male volunteer ) unit alcohol week ( unit = 1 glass wine ( 125 milliliter [ mL ] ) = 1 measure spirit = ½ pint beer ) . Loss donation 400 mL blood within 12 week prior entry trial . Participation another clinical trial within past 60 day . Any prescription counter medication intake within 2 week prior first administration tepotinib , include multivitamin herbal product ( St. John 's wort ) , exception acetaminophen ibuprofen . Consumption enzyme induce inhibit herbal drug , fruit juice beverage ( eg , grapefruit , grapefruit juice , Seville orange , quinine [ tonic water ] , star fruit ) , consumption poppy seed within 3 day prior first administration investigational medicinal product . Excessive consumption beverage contain xanthine ( ( &gt; ) 5 cup coffee day equivalent ) inability stop caffeine consumption resident trial site . Continued use caffeine ( less equal ( = &lt; ) 3 cups/day ) caffeine contain drink food , eg , coffee , tea , chocolate , Red Bull , cola ( 1 caffeine unit contain follow item : 1 [ 6 ounce ( oz ) ] cup coffee , 2 [ 12 oz ] can cola , 1 [ 12 oz ] cup tea , ½ [ 4 oz ] cup energy drink [ eg , Red Bull ] , 3 oz chocolate ) . Legal incapacity limit legal capacity . Unlikely comply protocol requirement , instruction trial related restriction ; eg , uncooperative attitude , inability return followup visit , improbability complete trial . Volunteer Investigator SubInvestigator , research assistant , pharmacist , trial coordinator , staff relative thereof directly involve conduct trial . Vulnerable volunteer ( eg , person keep detention ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>healthy volunteer</keyword>
	<keyword>Tepotinib</keyword>
	<keyword>Mesenchymal-epithelial transition factor</keyword>
	<keyword>Translocated promoter region</keyword>
</DOC>